Macrophage Plasticity in Cancer Therapy: Function, Timing, and Tradeoffs

Tumor-associated macrophages (TAMs) are considered to be one of the most attractive targets in cancer therapy but attempts to target them have produced variable and often contradictory results. Their phenotype and function are shaped by developmental origin, spatial niche, metabolic conditions, immune context, and treatment history. For this reason, TAM-directed therapy should not be approached as a simple problem of depletion or repolarization, but as a problem of function and timing. This framework integrates converging evidence from multiple independently reported studies of stage-, sequence-, and context-dependent macrophage targeting into a single decision structure, rather than proposing a new biological mechanism. We discuss here recurrent macrophage functions in solid tumors, including vascular support, matrix remodeling, immune exclusion, tumor-cell survival, antigen presentation, and tissue repair after therapy. We then consider how these functions affect the choice between depletion, recruitment blockade, reprogramming, and activation, and why the same intervention may be beneficial, ineffective, or harmful depending on lesion state and treatment sequence. Particular attention is given to therapeutic windows, biomarker-guided personalization, and adverse consequences of TAM intervention, including toxicity, compensatory myeloid substitution, loss of protective immune functions, repair-driven relapse, and the selection of inflammation-adapted or macrophage-resistant tumor cells. Effective TAM therapy will require functional precision, temporal precision, dynamic reassessment, and explicit attention to macrophage plasticity as both an opportunity and a source of risk.